FDA Approves US Merck-Pfizer Cancer Treatment

FDA Approves US Merck-Pfizer Cancer Treatment
FDA Approves US Merck-Pfizer Cancer Treatment

Two months earlier than expected, the US Food and Drug Administration (FDA)  has greenlighted the use of Merck & Co’s multi-indication cancer treatment Keytruda in combination with Pfizer’s Inlyta as a treatment for previously untreated advanced renal cell carcinoma.

Early approval for Keytruda in the new application should give the combination a head start on competitive products, analysts said.

The Keytruda/Inlyta combination is expected to provide serious competition for Bristol-Myers Squibb’s immunotherapy combination of Opdivo and Yervoy, which is currently regarded as the “gold standard” for previously untreated advanced kidney cancer patients.

According to IBES data from Refinitiv, a financial risk strategic partnership between Thomson Reuters and private equity funds managed by Blackstone, Keytruda’s sales have surged past Opdivo’s, and the drug is expected to pad US Merck’s sales total by more than $10 billion in 2019.

Keytruda, which works by increasing the ability of the patient’s immune system to help detect and fight tumor cells, has recently been Merck’s most important revenue growth driver especially in the lung cancer field.

A study published earlier this year claims to have shown that some 90% patients who received the Keytruda/Inlyta combination were alive after 12 months, compared with about 78% of patients treated with an older Pfizer standalone therapy Sutent.

Company

Logo:

Merck & Co

126 East Lincoln Avenue
07065 Rahway
US

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.